Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a biopharmaceutical company dedicated to creating innovative medicines that significantly improve the lives of patients. Founded in 1998, Ironwood specializes in gastrointestinal (GI) therapeutics and has a strong focus on developing and commercializing treatments for chronic conditions of the GI tract.
The company's flagship product is a medicine designed for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This medicine, discovered and developed by Ironwood, is now fully commercialized and widely used to alleviate symptoms in patients, improving their quality of life.
Ironwood's research pipeline is robust, with multiple investigational medicines targeting both the upper and lower GI tract. The company leverages its expertise in gastrointestinal disorders and pharmacologic expertise in guanylate cyclases to develop new therapies that address unmet medical needs.
Beyond its core product, Ironwood is actively exploring new opportunities and expanding its portfolio through collaborative licenses, commercial agreements, and strategic acquisitions. These efforts aim to enhance the company's research, development, manufacturing, and marketing capabilities, thereby driving growth and innovation.
Recent achievements for Ironwood include the advancement of several clinical trials, promising data from ongoing research studies, and strategic partnerships aimed at enhancing product development and market reach. Financially, Ironwood continues to build value, achieving milestones that attract continued support from shareholders.
Ironwood Pharmaceuticals remains committed to its mission of making a difference for patients through the development of groundbreaking therapies. The company’s strong pipeline, dedicated team, and strategic initiatives position it as a leading player in the field of gastrointestinal therapeutics.
Ironwood Pharmaceuticals (Nasdaq: IRWD), a leading gastrointestinal healthcare company, announced management presentations at two key investor conferences. The events include the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 10:30 a.m. ET, and the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET. Live webcasts of these presentations will be available on Ironwood's website, with replays accessible for 14 days after the conferences. Ironwood is dedicated to advancing treatment for GI diseases, notably with its leading product LINZESS®.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported a strong financial performance for 2021, with total revenues reaching $414 million, driven largely by $400 million from U.S. LINZESS collaboration revenue. The company reported a GAAP net income of $528 million, boosted by a non-recurring tax benefit. Ironwood also made strategic advancements in its pipeline, initiating clinical studies for IW-3300 and CNP-104, targeting unmet medical needs in visceral pain and primary biliary cholangitis (PBC). The company ended 2021 with $620 million in cash and equivalents, positioning itself favorably for growth in 2022.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced an investor update conference call for its fourth quarter and full year 2021, scheduled for February 17, 2022, at 8:30 a.m. ET. Participants can dial in at (888) 330-2384 for US/Canada or (240) 789-2701 internationally, using conference ID 4671230. The call will be available for replay after 11:30 a.m. ET on the same day until March 3, 2022. Ironwood is focused on advancing treatments for gastrointestinal diseases, led by its product LINZESS®.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced strong financial guidance, projecting LINZESS to exceed
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced that CEO Tom McCourt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The presentation will be held virtually, and investors can access the live audio webcast via the company’s website. A replay will be available for 14 days post-conference. Ironwood is focused on advancing treatments for gastrointestinal diseases, including its flagship product LINZESS® for IBS-C and CIC.
Ironwood Pharmaceuticals announced the appointment of Sravan K. Emany as the new Chief Financial Officer effective December 6, 2021. Emany, who has extensive experience in financial strategy within the healthcare sector, will oversee all financial operations and report to CEO Thomas McCourt. McCourt expressed confidence that Emany's expertise will enhance Ironwood's impact on gastrointestinal (GI) healthcare and benefit shareholders. Previously, Emany held leadership roles at Integra LifeSciences and has 18 years in investment banking.
Ironwood Pharmaceuticals reported a strong third quarter in 2021, with GAAP net income of $55.8 million and adjusted EBITDA of $65.5 million. LINZESS prescription demand surged 12% year-over-year, driving U.S. net sales to $253 million, up 5% from the previous year. Ironwood ended the quarter with $574 million in cash. The company expanded its pipeline by entering into an option agreement with COUR Pharmaceuticals for CNP-104, targeting primary biliary cholangitis, a rare autoimmune disease. The firm anticipates 6% to 8% growth in LINZESS net sales for 2021.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced a collaboration with COUR Pharmaceutical for the investigational therapy CNP-104, aimed at treating Primary Biliary Cholangitis (PBC), a rare autoimmune disease affecting 133,000 people in the U.S. Ironwood will pay approximately
Ironwood Pharmaceuticals (NASDAQ: IRWD) will host its third quarter 2021 investor update conference call on November 4, 2021, at 8:30 a.m. ET. Interested participants can join via phone or webcast through the company's website. The call will be replayable starting November 4 at 11:30 a.m. ET until November 18, 2021. Ironwood is a leader in gastrointestinal healthcare, known for its innovation in treating GI diseases, specifically with its LINZESS® product for IBS-C and CIC. Founded in 1998, it is based in Boston, Massachusetts.
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
What does Ironwood Pharmaceuticals specialize in?
What is Ironwood's flagship product?
When was Ironwood Pharmaceuticals founded?
What are some of Ironwood's recent achievements?
How does Ironwood plan to expand its research and development capabilities?
What areas does Ironwood's research pipeline target?
What other conditions, besides IBS-C and CIC, is Ironwood working on?
How does Ironwood build value for its shareholders?
Where is Ironwood Pharmaceuticals listed?
What is the company's mission?
